Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term lymphoma. Found 31 abstracts

no pagination
Hayakawa K, Li YS, Shinton SA, Bandi SR, Formica AM, Brill-Dashoff J, Hardy RR. Crucial Role of Increased Arid3a at the Pre-B and Immature B Cell Stages for B1a Cell Generation. Frontiers in immunology. 2019 Mar;10:457.   PMCID: PMC6428705
Prabhu VV, Talekar MK, Lulla AR, Kline CL, Zhou L, Hall J, Van den Heuvel AP, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell cycle (Georgetown, Tex). 2018 Feb 19;17(4):468-78.   PMCID: PMC5927637
Isoda T, Moore AJ, He Z, Chandra V, Aida M, Denholtz M, Piet van Hamburg J, Fisch KM, Chang AN, Fahl SP, Wiest DL, Murre C. Non-coding Transcription Instructs Chromatin Folding and Compartmentalization to Dictate Enhancer-Promoter Communication and T Cell Fate. Cell. 2017 Sep 21;171(1):103-119e18.   PMCID: PMC5621651
Prouet P, Giri S, Wiedower E, Fintel A, Yaghmour G, Lamb EP, Deneve J, Fleming M, Dickson P, Chandler JC, Martin MG. Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality. Anticancer research. 2017 Feb;37(2):813-7.
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MH, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017 Jul;28(7):1436-47.   PMCID: PMC5834038
Barta SK, Joshi J, Mounier N, Xue X, Wang D, Ribera JM, Navarro JT, Hoffmann C, Dunleavy K, Little RF, Wilson WH, Spina M, Galicier L, Noy A, Sparano JA. Central nervous system involvement in AIDS-related lymphomas. Br J Haematol. 2016 Apr 07;173(6):857-66.   PMCID: 4900917
Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW. Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leukemia & lymphoma. 2016 Mar;57(3):635-43.   PMCID: PMC4798896
Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol. 2016 Oct 22;172(2):208-18.   PMCID: PMC4710555
Lee HO, He X, Mookerjee-Basu J, Zhongping D, Hua X, Nicolas E, Sulis ML, Ferrando AA, Testa JR, Kappes DJ. Disregulated expression of the transcription factor ThPOK during T-cell development leads to high incidence of T-cell lymphomas. Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7773-8.   PMCID: 4485124
Talekar MK, Allen JE, Dicker DT, El-Deiry WS. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell cycle (Georgetown, Tex). 2015 Aug;14(15):2422-8.   PMCID: PMC4614396
Rao SY, Lee SY, Gutierrez A, Perrigoue J, Thapa RJ, Tu ZG, Jeffers JR, Rhodes M, Anderson S, Oravecz T, Hunger SP, Timakhov RA, Zhang RG, Balachandran S, Zambetti GP, Testa JR, Look AT, Wiest DL. Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood. 2012 Nov;120(18):3764-73.   PMCID: PMC3488889
Wang SZ, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunology Immunotherapy. 2012 Jan;61(1):49-61.   PMCID: PMC3517883
Weiss RF, Miller MG, Cronin JF, Hensley HH, Joshi ID, Smith MR. Parametric Model of Combination Therapy for Non-Hodgkin Lymphoma. Plos One. 2012 Dec;7(12):e51736.   PMCID: PMC 3522695
Gondi V, Bernard JR, Jabbari S, Keam J, Bernstein KL, Dad LK, Li L, Poppe MM, Strauss JB, Chollet CT. RESULTS OF THE 2005-2008 ASSOCIATION OF RESIDENTS IN RADIATION ONCOLOGY SURVEY OF CHIEF RESIDENTS IN THE UNITED STATES: CLINICAL TRAINING AND RESIDENT WORKING CONDITIONS. International Journal of Radiation Oncology Biology Physics. 2011 Nov;81(4):1120-7.   PMCID: *
Hoppe RT, Advani RH, Ai WY, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J, Nccn Clinical Practice Guidelines, Rbone Pp VP, Nellos Gp VP, Nellos Gp VP. NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network. 2011 Sep;9(9):1020-58.   PMCID: not NIH funded
Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. Leukemia & lymphoma. 2006 Sep;47(9):1902-7.
Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group trial 98-01. Journal of Clinical Oncology. 2005 Apr;23(10):2145-54.
Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DH, Berlfein JR, Ding E, Grillo-Lopezs AJ. Phase I/II Y-90-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC- Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. European Journal of Nuclear Medicine. 2000 Jul;27(7):766-77.
Schilder R. Rituximab immunotherapy. Cancer Biotherapy and Radiopharmaceuticals. 1999 Aug;14(4):237-40.
Young NA, Al-Saleem T. Hematopathologists and cytopathologists: Enemies or allies?. Diagnostic Cytopathology. 1999 Nov;21(5):305-6.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term lymphoma

lymphoma anti-cd20 monoclonal-antibody rituximab efficacy Onc201 immunotherapy leukemia Lin28b i-131 Non-coding transcription bone-marrow-transplantation T cell development non-Hodgkin's lymphoma drug therapy multiple myeloma classical Hodgkin disease arro surveys Association of Residents in Radiation Oncology acute lymphoblastic-leukemia bcl-2 Carfilzomib PATTERN either primary CBCL or low-grade effective in treating of CBCL combined-modality fine-needle aspiration Child activation esophagitis Non-Hodgkin Lymphoma TNF-Related Apoptosis-Inducing Ligand Tumor Cell Line treatment strategies prognostication AIDS-related lymphoma Toll-like receptor 4 agonist central nervous system relapse development single-loop domain clinical responses occurred in all five patients Three patients have phase-iii chemotherapeutic immunoglobulin sequences 90 Zevalin imipridone concurrent chemotherapy 2007 doloff da-v5-ps1 Heterocyclic Compounds with 4 or More Rings loop extrusion yttrium vorinostat tumor necrosis family TNF transgenic mice CHOP CHEMOTHERAPY Hodgkin disease intravenous infusions of 375 mg death receptor 5 DR5 apoptosis stem-cell transplantation Antineoplastic Agents cancer cutaneous site of large-cell lymphoma that developed after 3 years in gene Apoptosis ThPOK FOLLICULAR-GROWTH DENDRITIC CELLS phase 1 clinical trial Tumor Necrosis Factor Receptors mantle cell lymphoma metabolism with rituximab given as a single agent for four weekly therapy treatment 19 ongoing complete clinical remissions with a median follow-up of 17 Residency training present an attractive alternative when radiation therapy is carboplatin NCCN Guidelines oncology-group was given at 375 mg initiated Trail follicular Targeted therapy lymphocyte predominance TUMOR BURDEN AB Optimal treatment of cutaneous B-cell lymphoma (CBCL) is yet to be intensification and 39 months post achievement of complete remission One patient died acquired immunodeficiency syndrome TNF-related apoptosis-inducing ligand TRAIL 2007 doloff da-v5-ps23 phase-i radiation-therapy maintenance therapy B1a if m(2) Maintenance therapy positron-emission-tomography receptor agonists non-Hodgkin lymphoma radioimmunotherapy SYSTEMIC THERAPY m(2) once every 2-3 months Objective quality-of-life B-1 development antisense oligonucleotides complementary b-cell compartmentalization study-group ghsg non-Hodgkin's lymphoma NHL remission One patient received local radiotherapy to a solitary phase separation lymphomas with relapses limited to the skin Rituximab appears to Tumor Biomarkers Nhl B cell chemotherapy IDEC-Y2B8 update transcript EORTC CLASSIFICATION dosimetry combined response criteria subclassification modality therapy t-cell development negative predictive-value residency drug effects immunotherapeutic approaches p53 Neoplasia no recurrences of either grade CBCL involved-field radiotherapy waterfall plots fine-needle-aspiration Survey proteasome inhibition at age 87 years from a non-related cause after 55 years of complete Cell Survival Fdg-pet Radiation oncology cohesin cutaneous Tic10 translational control expression Cytarabine Arid3a chemoradiation ELDERLY-PATIENTS contraindicated or unwanted Additional collaborative studies are
Last updated on Wednesday, February 05, 2020